Advanced Search

 

Study ID Status Title Patient Level Data
COL30528 Completed An open label study to evaluate long term (96 weeks) safety and efficacy of switch to TRIZIVIR after first line quadruple induction therapy: AZLF 3006 – Suburbs 2
COL30573 Completed Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection
COL30574 Completed A phase IIIB, non-comparative, single arm, open-label, multicenter study on antiviral efficacy and safety of the approach “Induction- Maintenance” in patients with HIV-1 infection naïve to antiretroviral therapy. A 72-week study on the scheme: induction with TRIZIVIR® + SUSTIVA® or COMBIVIR® + SUSTI
COL40263 Completed A Pilot, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of a Once-Daily Regimen of Trizivir in Combination with Tenofovir Disoproxil Fumarate in Antiretroviral Therapy-Naïve Subjects with Viral Loads ?30,000 copies/mL
COL40287 Completed The Pharmacokinetic Interaction of a Triple Protease Inhibitor Regimen Containing Fosamprenavir, Lopinavir, and Ritonavir in Healthy Volunteers
COLA2012 Completed A Phase II, 192-Week, Uncontrolled, Open-Label Study Designed to Evaluate the Safety and Efficacy of Novel and Highly Potent Antiretroviral Therapy (Protease Inhibitor and Nucleoside Reverse Transcriptase Inhibitor Based) in Subjects Acutely Infected with HIV-1. (GW QUAD 3)
COLA3003 Completed A Phase II, 48-Week, Uncontrolled, Open-Label Study Designed to Evaluate Cellular Dynamics and Immune Restoration In Peripheral Blood and Lymphoid Tissue in Antiretroviral-Naïve, HIV-Infected Subjects Receiving a Triple-Drug Regimen Comprised of Amprenavir (600mg BID), Ritonavir (100mg BID), Aba ...
COLA4005 Completed A Phase II, Open-Label, Randomized Study of the Efficacy and Safety of EPIVIR 150mg Twice-Daily Versus EPIVIR 300mg Once-Daily When Administered for 24 Weeks in Combination with FDA-Approved Dosage Regimens of ZERIT and Either CRIXIVAN or VIRACEPT in Subjects with HIV-1 Infection
COR100216 Completed A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH). Study Listed on ClinicalStudyDataRequest.com
COR103560 Terminated A Randomized, Double-blind, Positive-Controlled, Multicenter Study Comparing the Efficacy of Carvedilol Phosphate Modified Release Formulation (COREG™ MR) and Metoprolol Succinate Extended Release (Toprol-XL®) on the Reduction of Microalbuminuria in Patients with Hypertension and Microalbuminuria. Study Listed on ClinicalStudyDataRequest.com
COR103561 Completed A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Phosphate Modified Release Formulation (COREG- MR) with Metoprolol Succinate (TOPROL XL) on the Lipid Profile in Normolipidemic, or Mildly Dyslipidemic Hypertensive Patients Study Listed on ClinicalStudyDataRequest.com
COR111096 Completed COR111096, A Randomized, Double-Blind, Active-Controlled, Parallel Group, Multicenter Study Comparing the Proportion of Subjects with Stage 1 or 2 Essential Hypertension Who Achieve Target Blood Pressure While Receiving Either carvedilol CR + lisinopril or lisinopril Monotherapy Study Listed on ClinicalStudyDataRequest.com
CP-97-011 Completed Phase II study of Iodine-131 anti-B1 antibody for 1st or 2nd relapsed indolent B-cell lymphomas or B-cell lymphomas that have transformed to a more aggressive histology.Note: Extensive searching has revealed that no clinical study report is available for this study.
CP-97-012 Completed Phase II study of iodine I 131 Tositumomab for non-Hodgkin’s lymphoma patients who have previously received Rituximab
CP-98-018 Completed A phase I, dose-escalation, open label, multicenter study of Iodine-131 anti-B1 antibody for intermediate- and high-risk B-cell chronic lymphocytic leukemia Study Listed on ClinicalStudyDataRequest.com
CP-98-020 Completed Expanded access study of Iodine-131 anti-B1 antibody for relapsed/refractory low-grade and transformed low-grade non-Hodgkin’s lymphoma
CP-98-021 Completed Retreatment study of patients with non-Hodgkin’s lymphoma who have previously responded to iodine I 131 Tositumomab
CP-98-025 Completed Fludarabine monophosphate followed by Iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin’s lymphomaNote: Extensive searching has revealed that no clinical study report is available for this study.
CP-98-028 Completed Phase 1, dose-escalation study of Iodine-131 anti-B1 antibody for patients with previously treated non-Hodgkin’s lymphoma with more than 25% bone marrow involvementNote: Extensive searching has revealed that no clinical study report is available for this study.
CP-99-036 Completed Phase II multicenter study of CVP followed by Iodine-131 anti-B1 antibody for patients with untreated low-grade non-Hodgkin’s lymphoma.Note: Extensive searching has revealed that no clinical study report is available for this study.
CPE107602 Completed A Phase I, Open-Label, Dose-Escalation, First Time in Human Study to Evaluate the Safety Profile, Pharmacokinetics, and Pharmacodynamics of GSK923295 in Subjects with Refractory Cancers
CR2100597 Completed A randomised, double-blind, placebo controlled, 3-way crossover study to evaluate the pharmacodynamics of SB-656933-AAA following single doses in healthy adult subjects undergoing ozone challenge.
CR2100609 Completed A randomised, double-blind, placebo controlled, dose ascending, parallel group study to evaluate the safety, tolerability, steady state pharmacokinetics and pharmacodynamics of SB-656933-AAA following repeated doses in healthy adult subjects. The pharmacokinetic interaction between repeated doses of SB-656933-AAA and single dose of simvastatin will also be assessed
CR2111256 Completed A randomized, double-blind, placebo controlled study to evaluate the safety, tolerability, and pharmacokinetics of SB-656933 following 14 days repeat dosing in healthy male smokers.
CR219039 Completed A dose ranging study to assess the effect of pre-treatment with a single dose of inhaled fluticasone propionate (2 mg, 0.5 mg) on lung inflammation following challenge with inhaled ozone and intermittent exercise in healthy volunteers, relative to placebo. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.